Cargando…

1026. Ertapenem Use During Antibiotic Stewardship Interventions in Community Hospitals

BACKGROUND: Antimicrobial stewardship programs (ASP) promote the judicious use of antimicrobials to reduce antimicrobial resistance and improve patient outcomes. In our institution, we identified the overutilization of ertapenem and implemented several interventions to decrease its usage. The object...

Descripción completa

Detalles Bibliográficos
Autores principales: Peterson, Nathan, Castro, Sarah, Barbosa, Felipe, Yoon, Jungwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811182/
http://dx.doi.org/10.1093/ofid/ofz360.890
_version_ 1783462418948554752
author Peterson, Nathan
Castro, Sarah
Barbosa, Felipe
Yoon, Jungwon
author_facet Peterson, Nathan
Castro, Sarah
Barbosa, Felipe
Yoon, Jungwon
author_sort Peterson, Nathan
collection PubMed
description BACKGROUND: Antimicrobial stewardship programs (ASP) promote the judicious use of antimicrobials to reduce antimicrobial resistance and improve patient outcomes. In our institution, we identified the overutilization of ertapenem and implemented several interventions to decrease its usage. The objective of this study was to assess the impact of these interventions on ertapenem use, rates of surgical site infection (SSI), carbapenem-resistant Enterobacteriaceae (CRE), and hospital-onset Clostridioides difficile infection. METHODS: This was a retrospective study conducted in 3 community hospitals in Iowa and Illinois using surveillance of anonymized antibiotic and infection control data from 2015 to 2018. Target ASP interventions included a daily retrospective review of ertapenem use, alternative alerts to providers through electronic health records (EHR), carbapenem restriction to infectious disease (ID) providers, and educational meetings with high-use provider groups. The primary outcome was the usage trend of ertapenem, and secondary outcomes were rates of SSI, CRE, and hospital-onset C. difficile infection. Interrupted time series analysis was performed to assess changes in the rates over the study period. RESULTS: An overall significant reduction in ertapenem use was observed in all 3-community hospitals from 2015 to 2018. Ertapenem days of therapy adjusted for case-mix index per 1000 patient-days was 11.2 in 2015 and 2.05 in 2018. Two breakpoints were identified; the addition of an ID trained pharmacist to the ASP (10/2016) and educational meetings with colorectal surgeons (5/2017). No significant difference was seen for hospital-onset C. difficile infection, SSI, or CRE. Purchase costs decreased for ertapenem by 81% in 2018 compared with 2015(P < 0.001). CONCLUSION: Adding an ID trained pharmacist to an ASP decreased usage of ertapenem. The majority of ertapenem use was for surgical prophylaxis, and our data suggested that educational meetings with a high-usage group were effective. Surgical site infection rates did not increase when narrower spectrum surgical prophylaxis was used. Overall hospital-acquired C. difficile rate was unchanged, possibly due to alternative antibiotic use. Our study suggests ASP interventions can be cost saving. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811182
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68111822019-10-29 1026. Ertapenem Use During Antibiotic Stewardship Interventions in Community Hospitals Peterson, Nathan Castro, Sarah Barbosa, Felipe Yoon, Jungwon Open Forum Infect Dis Abstracts BACKGROUND: Antimicrobial stewardship programs (ASP) promote the judicious use of antimicrobials to reduce antimicrobial resistance and improve patient outcomes. In our institution, we identified the overutilization of ertapenem and implemented several interventions to decrease its usage. The objective of this study was to assess the impact of these interventions on ertapenem use, rates of surgical site infection (SSI), carbapenem-resistant Enterobacteriaceae (CRE), and hospital-onset Clostridioides difficile infection. METHODS: This was a retrospective study conducted in 3 community hospitals in Iowa and Illinois using surveillance of anonymized antibiotic and infection control data from 2015 to 2018. Target ASP interventions included a daily retrospective review of ertapenem use, alternative alerts to providers through electronic health records (EHR), carbapenem restriction to infectious disease (ID) providers, and educational meetings with high-use provider groups. The primary outcome was the usage trend of ertapenem, and secondary outcomes were rates of SSI, CRE, and hospital-onset C. difficile infection. Interrupted time series analysis was performed to assess changes in the rates over the study period. RESULTS: An overall significant reduction in ertapenem use was observed in all 3-community hospitals from 2015 to 2018. Ertapenem days of therapy adjusted for case-mix index per 1000 patient-days was 11.2 in 2015 and 2.05 in 2018. Two breakpoints were identified; the addition of an ID trained pharmacist to the ASP (10/2016) and educational meetings with colorectal surgeons (5/2017). No significant difference was seen for hospital-onset C. difficile infection, SSI, or CRE. Purchase costs decreased for ertapenem by 81% in 2018 compared with 2015(P < 0.001). CONCLUSION: Adding an ID trained pharmacist to an ASP decreased usage of ertapenem. The majority of ertapenem use was for surgical prophylaxis, and our data suggested that educational meetings with a high-usage group were effective. Surgical site infection rates did not increase when narrower spectrum surgical prophylaxis was used. Overall hospital-acquired C. difficile rate was unchanged, possibly due to alternative antibiotic use. Our study suggests ASP interventions can be cost saving. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811182/ http://dx.doi.org/10.1093/ofid/ofz360.890 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Peterson, Nathan
Castro, Sarah
Barbosa, Felipe
Yoon, Jungwon
1026. Ertapenem Use During Antibiotic Stewardship Interventions in Community Hospitals
title 1026. Ertapenem Use During Antibiotic Stewardship Interventions in Community Hospitals
title_full 1026. Ertapenem Use During Antibiotic Stewardship Interventions in Community Hospitals
title_fullStr 1026. Ertapenem Use During Antibiotic Stewardship Interventions in Community Hospitals
title_full_unstemmed 1026. Ertapenem Use During Antibiotic Stewardship Interventions in Community Hospitals
title_short 1026. Ertapenem Use During Antibiotic Stewardship Interventions in Community Hospitals
title_sort 1026. ertapenem use during antibiotic stewardship interventions in community hospitals
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811182/
http://dx.doi.org/10.1093/ofid/ofz360.890
work_keys_str_mv AT petersonnathan 1026ertapenemuseduringantibioticstewardshipinterventionsincommunityhospitals
AT castrosarah 1026ertapenemuseduringantibioticstewardshipinterventionsincommunityhospitals
AT barbosafelipe 1026ertapenemuseduringantibioticstewardshipinterventionsincommunityhospitals
AT yoonjungwon 1026ertapenemuseduringantibioticstewardshipinterventionsincommunityhospitals